echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > 13 latest endocrinology guidelines/consensus, all in one article|Guideline consensus

    13 latest endocrinology guidelines/consensus, all in one article|Guideline consensus

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Edited by Yimaitong, please do not reprint without authorization
    .

    Introduction: This article summarizes the recently released guidelines/consensus on endocrine diseases at home and abroad for teachers to view and download
    .

     China's Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly (2022 Edition) According to the seventh national census bulletin of the National Bureau of Statistics, in 2020, the population of the elderly aged 60 and above in China will reach 260.
    4 million, of which about 30% are diabetic patients (more than 95% are diabetic patients).
    Type 2 diabetes), diabetes prevention and treatment is one of the key actions of Healthy China (2019-2030)
    .

     Recently, the "Chinese Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly (2022 Edition)" was released in the "Chinese Journal of Internal Medicine".
    , The implementation of clinical measures for diagnosis and treatment, and continuously improve the overall management level of elderly diabetes
    .

    This article shares the contents of "Optimization of Treatment Strategies for Type 2 Diabetes in the Elderly" and "Drug Treatment of Hyperglycemia"
    .

     Related reading: [1] The 2022 edition of the "Chinese Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly" was released! [2] Prof.
    Zhao Weigang: Interpretation of "Guidelines for the Diabetes and Treatment of Type 2 Diabetes in the Elderly (2022 Edition)" [3] Prof.
    Tian Hui: Current Situation and Improvement Measures of Diabetes Management in the Elderly in China Principles of "Medical Nutrition Therapy" for Geriatric Diabetes[5] Interview with Prof.
    Ji Linong: The new version of "Guidelines for the Prevention and Treatment of Geriatric Diabetes" to promote the improvement of diabetes management in the elderly in ChinaDownload link: http://guide.
    medlive.
    cn/guideline/248952 Short-term type of diabetes Expert Consensus on Intensive Insulin Therapy (2021 Edition) Recently, the "Expert Consensus on Short-Term Intensive Insulin Therapy for Type 2 Diabetes (2021 Edition)" was published simultaneously in "Chinese Journal of Diabetes" and "International Journal of Endocrinology and Metabolism"
    .

    The consensus of this department is revised on the basis of the 2017 "Clinical Expert Guidance on Short-Term Intensive Insulin Therapy for Type 2 Diabetes", which provides a reference for the application of short-term intensive insulin therapy in clinical institutions at all levels
    .

    Related reading: "Expert Consensus on Short-Term Intensive Insulin Therapy for Type 2 Diabetes (2021 Edition)" Release and Download Link: http://rs.
    yiigle.
    com/CN115791202201/1348838.
    htm Chinese Expert Consensus on the Prevention and Treatment of Insulin Injection-Related Subcutaneous Fat Hyperplasia Subcutaneous fat hyperplasia is one of the common complications of insulin therapy, which affects insulin absorption and glycemic control
    .

    In order to standardize long-term insulin injection and reduce the incidence of subcutaneous adipose hyperplasia, this consensus clarifies the diagnosis and classification of subcutaneous adipose hyperplasia based on the epidemiology, risk factors, histopathological characteristics, pathogenesis and harm of subcutaneous adipose hyperplasia.
    And combined with China's national conditions, put forward three-level prevention recommendations, and advocate scientific insulin injection technology education and training for doctors, nurses, and patients
    .

    The consensus suggests that the prevention of subcutaneous fat hyperplasia should be the main focus, the injection site should be rotated correctly and regularly during insulin injection, and the one-time use of insulin injection needles is recommended
    .

     Related reading: The new concept of "tertiary prevention" is proposed, and the "Chinese Expert Consensus on the Prevention and Treatment of Insulin Injection-Related Subcutaneous Fatty Hyperplasia" is released! Download link: https://guide.
    medlive.
    cn/guideline/24869 Beijing Expert Consensus on the Quality Control Index System of Integrated Traditional Chinese and Western Medicine for Hashimoto's Thyroiditis (2021 Edition) The diagnosis and treatment and clinical management of institutions are not standardized enough, which affects the clinical efficacy and medical quality to a certain extent
    .

    Initiated by the Integrative Medicine Center of the China-Japan Friendship Hospital, led by the Department of TCM Surgery of the China-Japan Friendship Hospital and the Thyroid Disease Department of the Sun Simiao Hospital of Beijing University of Traditional Chinese Medicine, and supported by the Thyroid Disease Professional Committee of the Beijing Association of Integrative Medicine, it is organized by more than 10 hospitals in Beijing.
    19 Western medicine related experts formed a consensus expert writing group, and through 2 rounds of collective discussions, a consensus was finally formed
    .

    The content of this consensus involves clinical diagnosis of Hashimoto's thyroiditis, treatment of integrated traditional Chinese and Western medicine, efficacy evaluation, adverse reaction monitoring, satisfaction evaluation, health education, follow-up management, etc.
    , and a total of 24 medical quality control indicators
    .

    The formulation of this consensus will provide norms and references for the quality management of Hashimoto's thyroiditis in the diagnosis and treatment of Hashimoto's thyroiditis in China, and is conducive to improving the level of diagnosis and treatment of Hashimoto's thyroiditis
    .

     Download link: https://guide.
    medlive.
    cn/guideline/24680 International Guidelines for Clinical Practice of Traditional Chinese Medicine: Diabetes and Lipid Metabolism Based on the new evidence of evidence-based medicine for the prevention and treatment of diabetes and lipid metabolism diseases, Professor Guo Jiao of Guangdong Pharmaceutical University led the organization to compile the International Chinese Medicine Clinical Practice Guideline.
    Download link: https://guide.
    medlive.
    cn/guideline /24696 2021 ESA position statement: Assessment and pharmacological treatment of primary hyperparathyroidism in adults Assessment and Pharmacotherapy Consensus Statement
    .

    This article mainly provides guidelines for the evaluation and drug treatment of primary hyperparathyroidism in adults
    .

     Download link: https://guide.
    medlive.
    cn/guideline/24763 2022 AAN Practice Guidelines: Oral Medications and Topical Treatment of Painful Diabetic Polyneuropathy (Updated) American Academy of Neurology (AAN) Updates on Painful Diabetic Polyneuropathy Guidelines for oral medications and topical treatment of polyneuropathy
    .

    This article is an update to the 2011 guidelines for the management of diabetic peripheral neuralgia, focusing on topical and oral medications
    .

     Download link: https://guide.
    medlive.
    cn/guideline/24833 2022 ETA Guidelines: Management of Graves' Disease in Children In January 2022, the European Thyroid Association (ETA) released guidelines for the management of Graves' disease in children
    .

    Hyperthyroidism due to Graves' disease is relatively rare in children, and treatment options are relevant for adults, including antithyroid drugs (ATD), radioactive iodine (RAI), or thyroid surgery
    .

    This article mainly provides guidelines for the management of Graves' disease in children
    .

     Related reading: "2022ETA: Guidelines for the Management of Graves' Disease in Children" released! Focus on "Treatment of Hyperthyroidism in Children", and put forward "43 Recommendations" download link: https://guide.
    medlive.
    cn/guideline/24856 2021ABCD/RA Guideline: Treatment of Hypertension and Renin-Angiotension in Adult Patients with Diabetic Nephropathy In January 2022, the British Association of Clinical Diabetes (ABCD) and the British Society of Nephrology updated the guidelines for the treatment of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic nephropathy
    .

    People with type 1 and type 2 diabetes are at risk of developing progressive chronic kidney disease (CKD) and end-stage renal failure
    .

    Hypertension is a major reversible risk factor for proteinuria, impaired renal function, end-stage renal disease, and cardiovascular disease in diabetic patients
    .

    This article reviews the current evidence and provides guidance on blood pressure control and the use of RAAS blockers in different stages of CKD in patients with type 1 and type 2 diabetes
    .

     Related reading: The latest clinical guidelines are released, and it is no longer difficult for patients with diabetic nephropathy to lower blood pressure! Download link: https://guide.
    medlive.
    cn/guideline/24858 2022AHA Scientific Statement: Integrated Management of Cardiovascular Risk Factors for Type 2 Diabetes in Adults The integrated management of factors scientific statement states that cardiovascular disease remains the leading cause of death in diabetic patients, cardiovascular disease in diabetic patients is multifactorial, and controlling cardiovascular risk factors can significantly reduce cardiovascular events
    .

    The main update points of this article focus on the evidence and application of new hypoglycemic drugs, the impact of blood pressure control and the role of new lipid-lowering therapies
    .

     Related reading: Cardiovascular risk management in patients with type 2 diabetes, AHA releases the latest scientific statementDownload link: https://guide.
    medlive.
    cn/guideline/24900 2022ACSM consensus statement: Exercise/physical activity in patients with type 2 diabetes 2022, The American College of Sports Medicine (ACSM) released a consensus statement on exercise/physical activity for people with type 2 diabetes.
    This article is an update of the 2010 ACSM position statement on exercise and type 2 diabetes.
    The article briefly summarizes the current evidence and expands and makes it more explicit.
    the previous suggestion
    .

     Download link: https://guide.
    medlive.
    cn/guideline/24939 The 2022 American National Standards: Self-Management Education and Support for Diabetes The National Standards for Self-Management Education and Support for Diabetes are a key element of care for all people with diabetes and are primarily designed to provide People with diabetes provide the knowledge, skills and confidence to take responsibility for self-management
    .

    To this end, the American Diabetes Association issued this standard
    .

     Download link: https://guide.
    medlive.
    cn/guideline/25003 2021ABCD/UKKA clinical practice guidelines: management of hyperglycemia in adults with diabetic nephropathy The 2021 edition of the guidelines for the management of hyperglycemia in adults with diabetic nephropathy is an update to the 2018 edition of the guidelines, including A substantial proportion of people with diabetes develop chronic kidney disease, which is also a major cause of end-stage renal disease
    .

    This article provides practical guidance on the management of hyperglycemia in adults with diabetic nephropathy by reviewing and evaluating the available evidence
    .

     Related reading: Guidelines for blood sugar management in adult diabetic nephropathy patients are released, and 5 tables summarize all aspects of patients' medication! Download link: https://guide.
    medlive.
    cn/guideline/25031
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.